Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11692280 | 0.83 | EPHX1 (0.49) | ALDH1A1HPGDNPSR1KDM4EMAPT | |
| SCHEMBL28473708 | 0.83 | ALDH1A1 (0.83) | ALDH1A1HPGDACLYNPSR1KDM4E | |
| SCHEMBL7194613 | 0.81 | EPHX1 (0.44) | ALDH1A1HPGDNPSR1KDM4EMAPT | |
| SCHEMBL18813004 | 0.79 | LMNA (0.54) | ALDH1A1HPGDKDM4EMAPTGAA | |
| SCHEMBL910646 | 0.79 | ALDH1A1 (0.76) | ALDH1A1HPGDACLYNPSR1KDM4E | |
| SCHEMBL1285793 | 0.79 | ALDH1A1 (0.76) | ALDH1A1HPGDACLYNPSR1KDM4E | |
| SCHEMBL1286101 | 0.79 | ALDH1A1 (0.76) | ALDH1A1HPGDACLYNPSR1KDM4E | |
| SCHEMBL21119055 | 0.79 | ALDH1A1 (0.76) | ALDH1A1HPGDACLYNPSR1KDM4E | |
| SCHEMBL29881864 | 0.79 | ALDH1A1 (0.76) | ALDH1A1HPGDACLYNPSR1KDM4E | |
| SCHEMBL2639943 | 0.79 | ALDH1A1 (0.76) | ALDH1A1HPGDACLYNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260029-B1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2014-10-01 | — | — | EP | claimed |
| US-20110009629-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2011-01-13 | — | — | US | claimed |
| EP-2260029-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | Sandoz AG (CH) | 2010-12-15 | — | — | EP | claimed |
| WO-2009106486-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2009-09-03 | — | — | WO | claimed |
| EP-2260029-B1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20110009629-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2260029-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | Sandoz AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009106486-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009629-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | OPRK1, TACR1, CMA1 | ALDH1A1 1063/4885HPGD 356/4885ACLY 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.